- Home
- IPHA vs CIGL Comparison
IPHA vs CIGL Comparison
Compare IPHA & CIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- CIGL
- Stock Information
- Founded
- IPHA 1999
- CIGL 1997
- Country
- IPHA France
- CIGL Singapore
- Employees
- IPHA N/A
- CIGL N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- CIGL Diversified Commercial Services
- Sector
- IPHA Health Care
- CIGL Consumer Discretionary
- Exchange
- IPHA Nasdaq
- CIGL Nasdaq
- Market Cap
- IPHA 160.1M
- CIGL 145.9M
- IPO Year
- IPHA 2019
- CIGL 2025
- Fundamental
- Price
- IPHA $1.74
- CIGL $4.21
- Analyst Decision
- IPHA Strong Buy
- CIGL
- Analyst Count
- IPHA 1
- CIGL 0
- Target Price
- IPHA $11.00
- CIGL N/A
- AVG Volume (30 Days)
- IPHA 11.2K
- CIGL 675.3K
- Earning Date
- IPHA 09-11-2025
- CIGL 01-01-0001
- Dividend Yield
- IPHA N/A
- CIGL N/A
- EPS Growth
- IPHA N/A
- CIGL N/A
- EPS
- IPHA N/A
- CIGL N/A
- Revenue
- IPHA $20,831,349.00
- CIGL $10,490,668.00
- Revenue This Year
- IPHA $209.83
- CIGL N/A
- Revenue Next Year
- IPHA $83.15
- CIGL N/A
- P/E Ratio
- IPHA N/A
- CIGL N/A
- Revenue Growth
- IPHA N/A
- CIGL N/A
- 52 Week Low
- IPHA $1.29
- CIGL $2.12
- 52 Week High
- IPHA $3.51
- CIGL $31.06
- Technical
- Relative Strength Index (RSI)
- IPHA 42.70
- CIGL N/A
- Support Level
- IPHA $1.71
- CIGL N/A
- Resistance Level
- IPHA $1.90
- CIGL N/A
- Average True Range (ATR)
- IPHA 0.08
- CIGL 0.00
- MACD
- IPHA 0.00
- CIGL 0.00
- Stochastic Oscillator
- IPHA 47.62
- CIGL 0.00
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.